We offer a subscription service with a nightly email, research reports, SMS alerts, education, group chat and more. Click here to see our offerings and plans.
- A clinical-stage oncology company developing therapies called CAR-T and TCR that help the immune system hunt down and kill tumor cells
- Its lead program (AUTO1) is a Pivotal study in adult acute lymphoblastic leukemia (ALL) and Pediatric ALL
- Primary endpoint in the Pivotal study = overall response rate
- Key secondary endpoints = duration of response, MRD negative CR rate, and safety
- AUTL has 3 additional clinical programs in P1-2 of development